LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

LLY

1,050.93

+2.96%↑

JNJ

248.43

+2.06%↑

ABBV

231.99

+3.33%↑

NVS

168.32

+1.89%↑

MRK

123.72

+3.77%↑

Начало・Списък с акции・Kura Oncology Inc

Kura Oncology Inc

Затворен

СекторЗдравеопазване

8.73 0.92

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

8.66

Максимум

8.75

Ключови измерители
By Trading Economics
Приходи	-8M -74M
Продажби	5.5M 21M
Марж на печалбата	-357.186
Служители	192
EBITDA	-1.3M -74M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+245.25% upside

Дивиденти
By Dow Jones
Следващи печалби	5.03.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-121M 727M
Предишно отваряне	7.81
Предишно затваряне	8.73

Настроения в новините

By Acuity

44%

56%

117 / 352 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

5.575 / 6.6 Подкрепа & съпротива

Kura Oncology Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

27.02.2026 г., 23:53 ч. UTC

Горещи акции

Stocks to Watch: Aardvark Therapeutics, Blue Moon Metals

27.02.2026 г., 22:23 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals To Acquire Apex Germanium Mine From Teck Subsidiary

28.02.2026 г., 21:36 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28.02.2026 г., 15:20 ч. UTC

Печалби

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- 2nd Update

28.02.2026 г., 14:43 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28.02.2026 г., 14:38 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire's Abel Pledges to Follow Buffett's 'Framework' in First Shareholder Letter -- Update

28.02.2026 г., 13:47 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28.02.2026 г., 13:44 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Hathaway Earnings Slip on Decline in Insurance Results -- WSJ

28.02.2026 г., 13:14 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Berkshire Hathaway Operating Earnings Fell 30% in Fourth Quarter. There Were No Stock Buybacks. -- Barrons.com

28.02.2026 г., 02:32 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Calpers Buys Into Hot Chip And Quantum Stocks -- Barrons.com

28.02.2026 г., 02:00 ч. UTC

Придобивния, сливания и поглъщания

Six Months, 9 Offers and $81 Billion. How Hollywood's Nasty Takeover Was Won. -- WSJ

28.02.2026 г., 02:00 ч. UTC

Придобивния, сливания и поглъщания

Six Months, 9 Offers and $81 Billion. How -2-

28.02.2026 г., 00:01 ч. UTC

Придобивния, сливания и поглъщания

Paramount Issuing $47 Billion of Equity at Big Premium to Stock Price for Warner Bros. Deal -- Barrons.com

27.02.2026 г., 23:46 ч. UTC

Придобивния, сливания и поглъщания

Netflix Walks Away a Winner After Losing Warner Bros. to Paramount -- Barrons.com

27.02.2026 г., 23:33 ч. UTC

Придобивния, сливания и поглъщания

Paramount Issuing $47 Billion of Equity at Nearly 20% Premium to Current Stock Price -- Barrons.com

27.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Tech, Media & Telecom Roundup: Market Talk

27.02.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

27.02.2026 г., 21:30 ч. UTC

Печалби

Solventum Beat Wall Street Earnings Estimates. The Stock Falls. -- Barrons.com

27.02.2026 г., 21:30 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Warner Terminates Netflix Deal, Ending Monthslong Saga -- Market Talk

27.02.2026 г., 21:20 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals to Buy Apex Germanium and Gallium Mine From Teck >BMM

27.02.2026 г., 21:17 ч. UTC

Печалби

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

27.02.2026 г., 21:10 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals Evaluating Options for a New Processing Line at Springer Complex to Process the Apex Material

27.02.2026 г., 21:09 ч. UTC

Придобивния, сливания и поглъщания

Blue Moon Metals to Acquire the Apex Germanium and Gallium Mine From Teck

27.02.2026 г., 21:00 ч. UTC

Печалби

Nike: 3Q Results to Be Released March 31 to Accommodate for Several Holidays >NKE

27.02.2026 г., 20:31 ч. UTC

Придобивния, сливания и поглъщания

Netflix Receives $2.8B Termination Fee Under Terminated Warner Bros. Discovery Deal

27.02.2026 г., 20:24 ч. UTC

Пазарно говорене

Oil Gains on Increased Risk of U.S.-Iran Conflict -- Market Talk

27.02.2026 г., 20:23 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Post Modest Gains -- Market Talk

27.02.2026 г., 20:12 ч. UTC

Пазарно говорене

Nike Seen With Further Challenges in China -- Market Talk

27.02.2026 г., 19:44 ч. UTC

Пазарно говорене

Gold Caps Historic Month -- Market Talk

27.02.2026 г., 19:39 ч. UTC

Печалби

These Stocks Are Today's Movers: Netflix, Paramount, Block, Sunrun, Dell, Rocket Lab, Nvidia, CoreWeave, and More -- Barrons.com

Сравнение с други в отрасъла

Ценова промяна

Kura Oncology Inc Прогноза

Ценова цел

By TipRanks

245.25% нагоре

12-месечна прогноза

Среден 30.14 USD 245.25%

Висок 40 USD

Нисък 20 USD

Според 9 анализатори от Wall Street, предложили 12-месечна ценова цел за Kura Oncology Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

9 ratings

Купи

Задържане

Продай

Според 9 анализатори, дали борсови рейтинги на Kura Oncology Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.575 / 6.6Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

117 / 352 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.